Skip to main content
. 2020 Jun 17;29(156):190068. doi: 10.1183/16000617.0068-2019

TABLE 1.

Overview of clinical trials assessing cystic fibrosis transmembrane conductance regulator (CFTR) modulators in non-cystic fibrosis lung disease

Study name/NCT Author [ref.] Population Drug Results Sponsor
Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis Lambert [114] In vitro: HBE, smoke exposed cells Roflumilast and Ivacaftor Roflumilast restores CFTR activity, ASL recovery and height post smoke exposure in vitro. Effect was additive with ivacaftor.
Roflumilast combined with adenosine increases mucosal hydration in human airway epithelial cultures after cigarette smoke exposure Tyrrell [116] In vitro: HBE, smoke exposed cells Roflumilast Roflumilast improved cellular cAMP and ASL height recovery post smoke exposure.
A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. Sloane [31] In vitro: HBE In vivo: Smokers with and without COPD Ivacaftor Ivacaftor activated CFTR transport, reduced smoked induced impairment in vitro.
The Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor Augments Mucociliary Clearance Abrogating Cystic Fibrosis Transmembrane Conductance Regulator Inhibition by Cigarette Smoke. Raju [65] In vitro: smoke exposed cells Ivacaftor Ivacaftor partially restores ASL and CBF induced by cigarette smoke exposure.
Pilot evaluation of ivacaftor for chronic bronchitis Solomon [120] Chronic bronchitis: pilot study Ivacaftor Trend towards improved symptoms and sweat chloride.
Topic Trial NCT02135432 Rowe [121] COPD Ivacaftor Results pending
A randomized, placebo controlled 4-week study in COPD of QBW251, a potentiator of the CFTR protein Rowe [56] COPD QWB251 No improvement in lung clearance index. Improved sweat chloride, spirometry, inflammation, and sputum colonisation (figure 1). Novartis
Clearing Lungs with ENaC Inhibition in PCD NCT02343445 In progress PCD Ivacaftor±ENaC inhibitor (VX-371) In progress Vertex

HBE: human bronchial epithelium; ASL: airway surface liquid interface; CBF: ciliary beat frequency; ENaC: epithelial sodium channel; PCD: primary ciliary dyskinesia.